Patents by Inventor Ellen Garber

Ellen Garber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090324602
    Abstract: Antibodies and antibody fragments that bind to the receptor Fn14 and induce or enhance cell killing of Fn14-expressing cancer cells are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to induce death of a tumor cell and treat disorders and in a subject.
    Type: Application
    Filed: May 8, 2009
    Publication date: December 31, 2009
    Applicant: Biogen Idec MA Inc.
    Inventors: Ellen Garber, Linda Burkly, Jennifer Michaelson, Alexey Lugovskoy, Yen-Ming Hsu, Karl Hanf
  • Patent number: 7632501
    Abstract: The invention provides antibodies that bind to a plurality of ?-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same.
    Type: Grant
    Filed: July 11, 2008
    Date of Patent: December 15, 2009
    Assignee: Biogen IDEC MA Inc.
    Inventors: Antonin R. De Fougerolles, Victor E. Kotelianski, Carl Reid, Ellen Garber
  • Patent number: 7612178
    Abstract: The invention relates to antibodies which bind to insulin like growth factor receptor-1 (IGF-1R) and uses thereof, in particular in the diagnosis and treatment of cancer. Specific human and murine monoclonal antibodies which inhibit IGF-1R-mediated pro-survival and tumor proliferation pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human and murine monoclonal antibodies which block the ability of the ligands, insulin like growth factor 1 (IGF-1) and insulin like growth factor 2 (IGF-2) to bind to IGF-1R, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention further includes methods of diagnosing and treating cancer using antibodies of the invention.
    Type: Grant
    Filed: March 28, 2007
    Date of Patent: November 3, 2009
    Assignee: Biogen Idec MA Inc
    Inventors: Kandasamy Hariharan, Scott Glaser, Ellen Garber, Christilyn Graff, Christopher L. Reyes, Stephen Demarest
  • Publication number: 20090252729
    Abstract: The present invention features inter alia polypeptides comprising an Fc region comprising genetically-fused Fc moieties. In addition, the instant invention provides, e.g., methods for treating or preventing a disease or disorder in subject by administering the binding polypeptides of the invention to said subject.
    Type: Application
    Filed: May 14, 2008
    Publication date: October 8, 2009
    Inventors: Graham K. Farrington, Amna Saeed-Kothe, Ellen Garber, Alexey Alexandrovich Lugovskoy
  • Publication number: 20090252748
    Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.
    Type: Application
    Filed: March 24, 2009
    Publication date: October 8, 2009
    Inventors: Sha MI, R. Blake Pepinsky, Zhaohui Shao, Ellen A. Garber, Steven D. Miklasz
  • Publication number: 20090226442
    Abstract: The invention relates to antibodies which bind to RON (receptor d'origine nantais, MST1R) and uses thereof, in particular in the diagnosis and treatment of cancer. Specific antibodies which inhibit RON-mediated pro-survival and tumor proliferation pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific antibodies which block the ability of the ligand, MSP to bind to RON, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention further includes methods of diagnosing and treating cancer using antibodies of the invention.
    Type: Application
    Filed: January 22, 2009
    Publication date: September 10, 2009
    Inventors: Heather Huet, Veronique Bailly, Ellen Garber, Christilyn Graff, Steven Miklasz
  • Publication number: 20090099078
    Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are Nogo receptor antagonist polynucleotides. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, nucleic acids encoding the same and antagonist polynucleotides.
    Type: Application
    Filed: January 26, 2007
    Publication date: April 16, 2009
    Inventors: Daniel H.S. Lee, Dingyi Wen, R. Blake Pepinsky, Jane K. Relton, Xinzhong Wang, Alexey Lugovskoy, Werner Meier, Ellen A. Garber, Laura Silvian, Paul H. Weinreb
  • Publication number: 20090092601
    Abstract: Humanized antibodies to LT-?-R and methods of use thereof are provided.
    Type: Application
    Filed: June 30, 2008
    Publication date: April 9, 2009
    Applicant: Biogen Idec MA Inc.
    Inventors: Ellen Garber, Paul Lyne, Jose William Saldanha
  • Publication number: 20090054632
    Abstract: Hydrophobically-modified proteins and methods of making them are described. A hydrophobic moiety is attached to a surface amino acid residue of the protein. The hydrophobic moiety can be a lipid or a peptide. Alternatively, the protein can be derivatized by a wide variety of chemical reactions that append a hydrophobic structure to the protein. The preferred protein is of mammalian origin and is selected from the group consisting of Sonic, Indian, and Desert hedgehog. The hydrophobic moiety is used as a convenient tether to which may be attached a vesicle such as a cell membrane, liposome, or micelle.
    Type: Application
    Filed: August 20, 2007
    Publication date: February 26, 2009
    Applicants: Biogen Idec MA Inc., Curis, Inc.
    Inventors: R. Blake Pepinsky, Alphonse Galdes, Ellen A. Garber, Darren P. Baker, Jeffery A. Porter, Frederick R. Taylor, Kevin P. Williams, Russell C. Petter, Kathryn Strauch, Paul H. Weinreb, Dingyi Wen, Chenhui Zeng
  • Patent number: 7479539
    Abstract: A fusion polypeptide is described having the amino acid sequence X-Y-Z, or portion thereof, comprising the amino acid sequence of a hedgehog (X); Y is an optional linker moiety; and Z is a polypeptide comprising at least a portion of a polypeptide other than hedgehog. It is preferred that X is a human hedgehog. Mutants of hedgehog are also described.
    Type: Grant
    Filed: November 2, 2000
    Date of Patent: January 20, 2009
    Assignee: Curis, Inc.
    Inventors: Kathryn Strauch, Ellen A. Garber, Frederick R. Taylor
  • Publication number: 20090017028
    Abstract: The invention provides antibodies that bind to a plurality of ?-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same.
    Type: Application
    Filed: July 11, 2008
    Publication date: January 15, 2009
    Inventors: Antonin R. De Fougerolles, Victor E. Kotelianski, Carl Reid, Ellen Garber
  • Publication number: 20090010930
    Abstract: Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.
    Type: Application
    Filed: January 16, 2008
    Publication date: January 8, 2009
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Michael Karpusas, Paul D. Lyne, Jose William Saldanha, Ellen A. Garber
  • Publication number: 20080241163
    Abstract: Anti-Tweak antibodies are described.
    Type: Application
    Filed: November 26, 2007
    Publication date: October 2, 2008
    Applicant: Biogen Idec MA Inc.
    Inventors: Linda C. Burkly, Ellen Garber, Alexey Lugovskoy
  • Patent number: 7429644
    Abstract: Humanized antibodies to LT-?-R and methods of use thereof are provided.
    Type: Grant
    Filed: April 10, 2003
    Date of Patent: September 30, 2008
    Assignee: Biogen Idec MA Inc.
    Inventors: Ellen Garber, Paul Lyne, Jose William Saldanha
  • Patent number: 7429645
    Abstract: This invention concerns humanized antibodies specific for the lymphotoxin beta receptor (LT-?-R), cell lines that produce these antibodies, immunochemicals made from the antibodies, and diagnostic methods that use the antibodies. The invention also relates to the use of the antibodies alone or in combination with chemotherapeutic agent(s) in therapeutic methods.
    Type: Grant
    Filed: December 23, 2004
    Date of Patent: September 30, 2008
    Assignee: Biogen Idec MA Inc.
    Inventors: Ellen Garber, Kenneth Simon, Jose William Saldanha
  • Patent number: 7405277
    Abstract: The invention provides antibodies that bind to a plurality of ?-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same.
    Type: Grant
    Filed: May 27, 2004
    Date of Patent: July 29, 2008
    Assignee: Biogen Idec MA Inc.
    Inventors: Antonin R. De Fougerolles, Victor E. Kotelianski, Carl Reid, Ellen Garber
  • Publication number: 20080124278
    Abstract: The invention relates to aglycosyl anti-CD154 antibodies or antibody derivatives, characterized by a modification at the conserved N-linked site in the CH2 domains of the Fc portion of said antibody. The invention also relates to the treatment of immune response related diseases and inhibition of unwanted immune responses with such aglycosylated anti-CD154 antibodies or antibody derivatives thereof.
    Type: Application
    Filed: August 20, 2007
    Publication date: May 29, 2008
    Inventors: Frederick R. Taylor, Christopher D. Benjamin, Linda C. Burkly, Ellen A. Garber
  • Patent number: 7358054
    Abstract: Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.
    Type: Grant
    Filed: April 12, 2002
    Date of Patent: April 15, 2008
    Assignee: Biogen Idec Ma Inc.
    Inventors: Paul D Lyne, Ellen A Garber, Jose W Saldanha, Michael Karpusas
  • Publication number: 20070243194
    Abstract: The invention relates to antibodies which bind to insulin like growth factor receptor-1 (IGF-1R) and uses thereof, in particular in the diagnosis and treatment of cancer. Specific human and murine monoclonal antibodies which inhibit IGF-1R-mediated pro-survival and tumor proliferation pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human and murine monoclonal antibodies which block the ability of the ligands, insulin like growth factor 1 (IGF-1) and insulin like growth factor 2 (IGF-2) to bind to IGF-1R, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention further includes methods of diagnosing and treating cancer using antibodies of the invention.
    Type: Application
    Filed: March 28, 2007
    Publication date: October 18, 2007
    Applicant: Biogen Idec MA Inc.
    Inventors: Kandasamy Hariharan, Scott Glaser, Ellen Garber, Christilyn Graff, Christopher Reyes, Stephen Demarest
  • Publication number: 20070154476
    Abstract: Receptor coupling agents, including multivalent constructs comprising anti-TNF receptor binding moieties, for treating cancer and inhibiting tumor volume in a subject are disclosed.
    Type: Application
    Filed: September 21, 2006
    Publication date: July 5, 2007
    Inventors: Jeffrey Browning, Veronique Bailly, Ellen Garber